Sign In
Buy KRON
$0.88
+0 (+0%)
At Close: Sep 19, 2025
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host con
Kronos Bio Announces Participation in Upcoming Investor Conferences
04:05pm, Thursday, 01'st Jun 2023
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.65 per share a year ago.
5 Hot Penny Stocks To Watch This Week With Big News
09:02am, Monday, 09'th Jan 2023
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Kronos Bio's stock rallies after announcing drug-discovery deal with Roche
08:23am, Monday, 09'th Jan 2023
Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's ROG, -0.46% Genentech. Kronos has a drug discovery
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
11:17am, Monday, 12'th Dec 2022
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Kronos Bio Announces Participation in Upcoming Investor Conferences
04:05pm, Tuesday, 22'nd Nov 2022
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
11:17am, Tuesday, 22'nd Nov 2022
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Goldman Sachs Has 5 Stocks to Buy Under $10 With 100% to 800% Upside Potential
05:50am, Saturday, 29'th Oct 2022
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742
Kronos Bio Announces Participation in Upcoming Investor Conferences
04:05pm, Wednesday, 01'st Jun 2022
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious d
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022
10:08pm, Tuesday, 08'th Mar 2022 GlobeNewswire
Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma Posters also feature data from preclinical chordoma and sarcoma models KB-0742 is being evaluated in an ongoing Phase 1/2 trial
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference
12:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March 7-9, 2022.
Recap: Kronos Bio Q4 Earnings
08:43am, Friday, 25'th Feb 2022 Benzinga
Kronos Bio (NASDAQ: KRON ) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Kronos Bio missed estimated earnings by 2.73%, reporting an EPS of … Full story available on Benzinga.com
Kronos Bio GAAP EPS of -$1.13 misses by $0.03
10:33pm, Thursday, 24'th Feb 2022 Seeking Alpha
Kronos Bio press release (KRON): Q4 GAAP EPS of -$1.13 misses by $0.03.$339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway…
